New Survey Highlights Gap Between Perceived AI Readiness And Tested Disaster Recovery Capability 
Syngenta Deploys Tetra OS to Accelerate Scientific Discovery Through Industrial-Scale Data Automation Netacea engages with University of Nottingham and government funded scheme to advance threat detection and mitigation offering
Netacea reveals how the partnership contributed to evolving its product suite and helped cut onboarding…
Opera GX integrates CORSAIR iCUE to give a splash of color to gamers’ browsing
OSLO, Norway, Sept. 16, 2021 /PRNewswire/ — Opera GX is introducing iCUE integration that makes CORSAIR…
Launch of Oxitope Pharma, a biopharmaceutical start-up dedicated to the discovery and development of antibody-based medicines for the treatment of diseases caused by oxidative stress
PRESS RELEASE Launch of Oxitope Pharma, a biopharmaceutical start-up dedicated to the discovery and development…
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen…
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary…
Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021
Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging…
Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors
Interim results from ongoing Phase 1 dose-escalation study demonstrate safety and tolerability of repeat dosing…
Acacia Pharma Announces Initiation of Pivotal Study of Byfavo® in Pediatric Procedural Sedation
This announcement contains inside information for the purposes of Article 7 of the Market Abuse…
NICE Recommends BioCryst’s ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK
RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
Mountain Valley MD Holdings Announces Voluntary Retraction of a Reported Data Set, No Material Change to Business Plan Anticipated
TORONTO, Sept. 15, 2021 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or…
BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma…
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage…
X4 Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update…
Casma Therapeutics to Present at the UBS Virtual Biotechnology Private Company Symposium
CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) — Casma Therapeutics, Inc., a biotechnology company harnessing…
Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand Travere…
Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature
Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens…
BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit
SANTA MONICA, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a…
aTyr Pharma Announces Proposed Public Offering of Common Stock
SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical…